MDGL · Madrigal Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio
$427.39
+2.18 (+0.51%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$9.93B
Shares
23.23M
Volume · Nov 13
441.32K
Avg daily vol (3M)
354.09K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Madrigal Pharmaceuticals, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Madrigal Pharmaceuticals, Inc. (MDGL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-12-02
Madrigal Pharmaceuticals, Inc. (MDGL) December 2, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-12-01
Madrigal Pharmaceuticals, Inc. (MDGL) December 1, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-17
Madrigal Pharmaceuticals, Inc. (MDGL) November 17, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-03
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 Earnings Call Transcript
Revenue
$431.27M
▲ 50.1% YoY Diluted EPS
$1.83
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-08-11
Madrigal Pharmaceuticals, Inc. (MDGL) August 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-30
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2026 Earnings Call Transcript
Confident tone
ResDifera Commercial Performance
MASH Market Expansion
Intellectual Property / Patent Estate
Revenue
$364.25M
▲ 71.2% YoY Diluted EPS
$-1.99
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-10
Madrigal Pharmaceuticals, Inc. (MDGL) June 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript
Confident tone
F4C compensated cirrhosis indication expansion
MASH market opportunity and expansion
Path to peak sales and long-term outlook
Revenue
$311.34M
▲ 126.8% YoY Diluted EPS
$-3.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-03
Madrigal Pharmaceuticals, Inc. (MDGL) March 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-19
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Confident tone
Rezdiffra launch and net sales performance
F4C (compensated NASH cirrhosis) opportunity
Patent exclusivity
Revenue
$321.08M*
▲ 210.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2025 Earnings Call Transcript
Confident tone
Rezdiffra launch performance
Pipeline and MAESTRO-NASH
Gross to net dynamics
Revenue
$287.27M
▲ 362% YoY Diluted EPS
$-4.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2025 Earnings Call Transcript
Confident tone
Rezdiffra launch performance
F4c compensated MASH cirrhosis / OUTCOMES trial
Oral GLP-1 business development (MGL-2086)
Revenue
$212.80M
▲ 1353.8% YoY Diluted EPS
$-1.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript
Revenue
$137.25M
Diluted EPS
$-2.61
Gross margin
96.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript
Confident tone
U.S. Rezdiffra Launch Execution
Market Penetration & Growth Opportunity
F4c Cirrhosis Data & Label Expansion
Revenue
$103.32M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2024 Earnings Call Transcript
Confident tone
Rezdiffra US launch performance
Pipeline and long-term leadership in NASH
Business development and pipeline expansion
Revenue
$62.17M
Diluted EPS
$-4.92
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2024 Earnings Call Transcript
Confident tone
Patient education and disease awareness
Rezdiffra launch metrics
Wiring the system / physician activation
Revenue
$14.64M
Diluted EPS
$-7.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2024 Earnings Call Transcript
Confident tone
Rezdiffra U.S. launch progress
Clinical pipeline expansion
Patient access and reimbursement
Revenue
$0
Diluted EPS
$-7.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2022 Earnings Call Transcript
Revenue
$0
Diluted EPS
$-3.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q3
2021-11-04
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2021 Earnings Call
Revenue
$0
Diluted EPS
$-3.79
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–19 of 19 webcasts
Key facts
CIK
1157601
CUSIP
558868105
13F (30d)
343 filings
308 filers
Visit website
Investor relations